Navidea Biopharmaceuticals Schedules Third Quarter 2013 Financial Results Conference Call

- Conference call with investment community at 8:30 a.m. ET, November 6th –

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the third quarter 2013, on Wednesday, November 6, 2013 before the market opens. The announcement will be followed by a conference call with the investment community, at 8:30 a.m. ET.

Investors and the public are invited to listen to the conference call via telephone or live webcast:

Event:   Navidea Biopharmaceuticals Q3 2013 Financial Results Conference Call
Date/Time: Wednesday, November 6, 2013 at 8:30 a.m. ET
Webcast Link:

Dial-in Number – US: (888) 713-4214
Dial in Number – Int’l: (617) 213-4866
Participant Passcode: 42425304
Replay A webcast replay will be available on the Investor Relations section of our website under Calendar of Events until December 6, 2013.

Participants who would like to ask questions during the question and answer portion of the call must participate by telephone. For faster service on the day of the call, participants may pre-register for the telephonic call at: Pre-registrants will be issued a PIN number to use along with the Passcode when dialing into the live call which will provide quicker access to the conference by bypassing the operator upon connection. If not pre-registered, participants are encouraged to dial-in fifteen minutes before the conference call begins. Pre-registration is not necessary to listen to the live webcast or webcast replay. The webcast replay is expected to be available on our website approximately two to four hours after the live event.

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is developing multiple precision diagnostic products and platforms including NAV4694, NAV5001, Manocept™ and RIGScan™, to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Lymphoseek® (technetium 99m tilmanocept) Injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company’s pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit

Navidea Biopharmaceuticals
Brent Larson, Executive VP & CFO, 614-822-2330
Sharon Correia, Associate Director, Corporate Communications, 978-655-2686

Source: Navidea Biopharmaceuticals, Inc.